Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)

Slides:



Advertisements
Similar presentations
New Insights in the Understanding of Cholesterol Metabolism: The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Regulation of Low-Density.
Advertisements

Kirk Mykytyn, Ph.D. Department of Pharmacology
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial Z. Awan, N.G. Seidah, J.G.
Cholesterol Metabolism and the Concept of Dual Inhibition David E. Cohen, MD, PhD.
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
Overview Lipoprotein metabolism Digestive lipid metabolism
Kendrick Sparks, PGY3 September 17, 2015
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Discovery of a New Role of Human Resistin in Hepatocyte.
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.
Evolocumab Drugbank ID : DB09303.
By: Dr Israa Omar MBBS, MRCP, MSc pharmacology
Robert Roberts, MD, FRCPC, MACC  Canadian Journal of Cardiology 
The Latest Lipid Guidelines:
Nat. Rev. Cardiol. doi: /nrcardio
Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors
Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels
Dual regulation of the LDL receptor—Some clarity and new questions
Figure 7 Mendelian randomization of overlapping exposures
Antilipidaemic agents
An Endocrinology Clinic in Dyslipidemia
Nat. Rev. Cardiol. doi: /nrcardio
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
Cholesteryl Ester Transfer Protein Inhibitors
Figure 2 Hepatic action of functional foods and supplements
Figure 3 Metabolism pathway of antiplatelet agents
Figure 2 Binding properties of P2Y12-receptor inhibitors
Advances in Dyslipidemia: What Have We Learned From ACC 2017
What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?  Raul D. Santos  Atherosclerosis.
Figure 1 Newly discovered mechanistic pathways
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 Sterol regulatory element-binding
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Antiplatelet and anticoagulant pathways
Figure 1 Inducers of the NLRP3 inflammasome related
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Evaluating LDL-C Recommendations
Nat. Rev. Endocrinol. doi: /nrendo
Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
My Approach to the Patient With Familial Hypercholesterolemia
Nat. Rev. Cardiol. doi: /nrcardio
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,
New LDL-C Lipid Targets
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
Updates in Cardiovascular Medicine
Figure 5 Examples of biomarker-guided trials
New Therapeutic Approaches to the Treatment of Dyslipidemia
Figure 3 Challenges for big data applications in cardiovascular care
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.
Volume 130, Issue 6, Pages (May 2006)
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Copyright © 2016 Elsevier Inc. All rights reserved.
Nat. Rev. Cardiol. doi: /nrcardio
Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease  Guenther Silbernagel, MD, Iris Baumgartner, MD, Christoph Wanner, MD,
Figure 1 The major pathways of lipid metabolism
Lipid Updates From Spring 2019
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]
PCSK9 Inhibitors and Statin Intolerance
Nat. Rev. Cardiol. doi: /nrcardio
Insights in the Understanding of Cholesterol Metabolism:
in diabetic patients with mixed dyslipidemia
Fig. 2. Effects of CB_36 and its analogs in HepG2 cells
Presentation transcript:

Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown) Figure 1 | Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown). Statins inhibit cholesterol synthesis in the liver, ezetimibe blocks cholesterol absorption in the intestine, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors block the PCSK9-mediated degradation of LDL receptors. Grundy, S. M. (2016) Advances in treatment of dyslipidaemia Nat. Rev. Cardiol. doi:10.1038/nrcardio.2015.208